drugset / Trial / NCT03416816
A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, open label, multi-center study of orally administered DSP-0337 in adult subjects with advance solid tumors that are refractory to standard treatment, or for whom no effective therapy exists.
Timeline
- Start
- 2018-05-15
- Primary completion
- 2020-06-15
- Completion
- 2020-06-15
Outcome
Outcome not reported
Stopped (Business): “Alternate development strategy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DSP-0337 | Unknown | 200 mg | Oral |
| Subject | DSP-0337 | Unknown | 400 mg | Oral |
| Subject | DSP-0337 | Unknown | 600 mg | Oral |
| Subject | DSP-0337 | Unknown | 800 mg | Oral |
| Subject | DSP-0337 | Unknown | 1000 mg | Oral |